We did an open-label , randomised , 22 factorial trial in men with locally advanced prostate cancer ( either T2a N0 M0 prostatic adenocarcinomas with prostate-specific antigen [ PSA ] 10 g/L and a Gleason score of 7 , or T2b-4 N0 M0 tumours regardless of PSA and Gleason score ) .